Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Hasılat
824
824
837
753
678
690
Hasılat Artışı (YoY)
-2%
-2%
11%
11%
-2%
131%
Satınalma Maliyeti
247
247
252
236
202
197
Brüt Kâr
576
576
585
517
476
493
Satış, Genel ve İdari
537
537
560
565
514
537
Araştırma ve Geliştirme
106
106
113
88
85
81
İşletme Giderleri
644
644
673
653
600
619
Diğer Finansman Gelirleri (Giderleri)
0
0
-1
-4
0
0
Kâr Öncesi Gelir
-395
-395
-123
-262
-140
-57
Kira Vergisi Gideri
-29
-29
3
1
-28
-32
Net Kâr
-365
-365
-127
-263
-112
-27
Net Income Growth
Kâr Artışı
187%
187%
-52%
135%
315%
-49%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
93.5
92.6
90.6
82.8
80.6
78
Hisse Değişimi (Yıllık Üst Üste)
3%
2%
9%
3%
3%
4%
EPS (Diluted)
-3.91
-3.95
-1.4
-3.18
-1.39
-0.34
EPS Artışı
178%
181%
-56%
129%
309%
-51%
Öz sermaye akışı
-25
-25
-38
-184
-151
0
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
69.9%
69.9%
69.89%
68.65%
70.2%
71.44%
Faaliyet Kâr Marjı
-8.13%
-8.13%
-10.51%
-18.06%
-18.14%
-18.26%
Kâr Marjı
-44.29%
-44.29%
-15.17%
-34.92%
-16.51%
-3.91%
Özsermaye Karlılık Oranı
-3.03%
-3.03%
-4.54%
-24.43%
-22.27%
0%
EBITDA
-14
-14
-27
-75
-71
-64
EBITDA Marjinali
-1.69%
-1.69%
-3.22%
-9.96%
-10.47%
-9.27%
D&A EBITDA için
53
53
61
61
52
62
Faaliyet Kârı
-67
-67
-88
-136
-123
-126
Faaliyet Kâr Marjı
-8.13%
-8.13%
-10.51%
-18.06%
-18.14%
-18.26%
Verilen Vergi Oranı
7.34%
7.34%
-2.43%
-0.38%
20%
56.14%
Follow-Up Questions
Quels sont les états financiers clés de Myriad Genetics Inc ?
Selon le dernier état financier (Form-10K), Myriad Genetics Inc a un total d'actifs de $706, un bénéfice net kayıp de $-365
Quels sont les ratios financiers clés pour MYGN ?
Le ratio de liquidité de Myriad Genetics Inc est 2.08, la marge nette est -44.29, les ventes par action sont de $8.89.
Comment les revenus de Myriad Genetics Inc sont-ils répartis par segment ou géographie ?
Myriad Genetics Inc en büyük gelir kaynağı Hereditary Cancers olup, en son kar bildiriminde geliri 327,800,000 dir. Coğrafi olarak, United States , Myriad Genetics Inc için ana pazar olup, geliri 671,700,000 dir.
Myriad Genetics Inc est-elle rentable ?
hayır, selon les derniers états financiers, Myriad Genetics Inc a un bénéfice net kayıp de $-365
Myriad Genetics Inc a-t-elle des passifs ?
evet, Myriad Genetics Inc a un passif de 338
Combien d'actions en circulation Myriad Genetics Inc a-t-elle ?
Myriad Genetics Inc a un total d'actions en circulation de 93.5